Just In
- 5 hrs ago Summer Style: 6 Must-Try Colors To Stay Fashionably Cool Like B-Town Divas!
- 7 hrs ago Belgian Man Cleared Of Drunk Driving Because His Body Produces Alcohol Due To A Rare Condition
- 8 hrs ago Amitabh Bachchan's Youthful Avatar In Kalki 2898 AD Is Impressive, Check Actors Who Sported Digital De-Aging!
- 8 hrs ago Full Moon In Scorpio In April 2024: How It Will Affect 12 Zodiac Signs
Don't Miss
- Sports Boxing: India announce strong 50-member squad for ASBC Asian U-22 & Youth Boxing Championship 2024; Olympic-bound Preeti to spearhead campaign
- News WATCH Viral Video: Military Horses Break Loose In UK, 4 Injured
- Technology iQOO Z9 Turbo Launched in China: Snapdragon 8s Gen 3, 16GB RAM, and More
- Movies Salaar 2: Vijay Deverakonda's Cameo In Prabhas-Prashanth Neel's Hyped Sequel Shouryaangaparvam? All We Know
- Finance Rs 24/Share Dividend: Buy Large Cap FMCG Stock, Highest TP Rs 2900: Motilal, PL, 5paisa Bullish
- Education MP Board Class 10th, 12th Results 2024, Know Alternative Ways to Check Your Result
- Automobiles Toyota Fortuner Leader Edition – Top Things You Need To Know
- Travel Mumbai Opens BMC Headquarters For Exclusive Heritage Tour
Zydus Lifesciences Launches Oral Drug Bemdac For Treating Bad Cholesterol
Zydus Lifesciences on Friday said it has launched in India its Bempedoic acid drug under the Bemdac brand for treatment of uncontrolled levels of bad cholesterol.
Bemdac (Bempedoic acid) is a new class of drug which is orally administered and offers a new line of treatment for patients suffering from uncontrolled levels of LDL-Cholesterol (LDL-c) despite lifestyle modifications and the use of maximum tolerated dose of statins, which form the cornerstone of dyslipidemia management, the company said in a regulatory filing.
"With Bemdac we are happy to introduce a first-in-India therapy to address the unmet medical need of people suffering from uncontrolled LDL-c," Zydus Lifesciences Managing Director Sharvil Patel said.
Stating that Bemdac is an important addition to Zydus' portfolio of medicines for managing dyslipidemia and cholesterol, Patel said the mission is to empower patients with a better quality of life through effective disease management and with Bemdac the company has taken a great leap ahead in this endeavour.
The company said LDL-c is often referred to as bad cholesterol since it gets deposited in the walls of the blood vessels, increasing the chances of health problems like a heart attack or stroke.
Uncontrolled LDL-c is a major risk factor for developing cardiovascular diseases. Citing various studies, Zydus said, 8 out of 10 Indians are dyslipidemic1 and 112 million adults suffer from high levels of LDL-c; 7 out of 10 dyslipidemia patients who are on statin treatment continue to suffer from uncontrolled LDL-c.
Besides this, 5.4 million Indians are found to be intolerant to statin therapy, it added. Bempedoic acid has also shown to have good results in patients not able to tolerate statins and those who do not respond to statins. This is a huge unmet healthcare need that Bemdac addresses, Zydus claimed.